No­var­tis gets a boost in block­buster mul­ti­ple scle­ro­sis race with Roche

In the first step of what’s like­ly to be a long and up­hill bat­tle for the drug­mak­er, the FDA has ac­cept­ed No­var­tis’s BLA sub­mis­sion for a new mul­ti­ple scle­ro­sis drug and giv­en it pri­or­i­ty re­view. The PDU­FA date for the po­ten­tial block­buster drug is in June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.